Tagged with USA

USA Tatsuya Kaihara, head of US operations for Japanese eyecare specialist Santen, describes his excitement at bringing two new ophthalmic advancements to the US market, the similarities, differences, and synergies of Japanese and American innovation, and the challenges of building a unified corporate culture.   This is a very exciting moment…

USA The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their vital role leading operations in the world’s most innovative and lucrative pharma market, translating global cultures to a US reality, and the challenges of attracting and retaining…

USA Ahead of the 2020 US National Organization for Rare Disorders (NORD)’s Rare Diseases and Orphan Products Breakthrough Summit, NORD president and CEO Peter L. Saltonstall outlines his hopes for the Summit, the impact of COVID-19 on the US rare disease community, and touches on the current reality and potential problems…

USA Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under development, and why an open and collaborative approach among US healthcare stakeholders is needed if the significant legal and practical barriers are to be overcome.   The…

USA Gary Zieziula, president & region head North America for Kyowa Kirin, a specialty care-focused Japan-based global pharma company, highlights the tremendous growth the affiliate has seen over the past three years on track to become a USD 500 million+ organization within the next year; the exciting products and assets that…

USA In the aftermath of the fiery first presidential debate between incumbent Donald Trump and Democratic Party rival Joe Biden, we round up the latest on how the latest developments in US politics stand to affect pharma and healthcare. Featured are the two candidates’ proposals for drug pricing reform and Trump’s…

USA Dr Peter Marks MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), highlights the Center’s contributions related to the regulatory science behind vaccine development, including vaccines to prevent COVID-19; the Center’s efforts to facilitate the advancement of the field…

USA Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive order on medicine pricing, its wider impact on other high income economies, and why a Democratic victory in the upcoming presidential election will not see this issue go away.  …

USA As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM) president & CEO Chip Davis; Carol Lynch, president of Sandoz US, head of Sandoz North America and member of the Sandoz Executive Committee; and Amgen’s biosimilars business…

USA With US still the reigning global champion in biotech innovation, the dynamic and vibrant biopharma ecosystem in the world’s largest healthcare market continues to churn out ground-breaking innovations with companies aspiring to follow in the footsteps of success stories like Regeneron, Celgene, and Amgen. Once US biotechs achieve the significant…

USA Michael Ciarametaro, VP for Research at the US National Pharmaceutical Council (NPC), outlines issues surrounding the outdated Medicaid Best Price (MBP) and why there is a dire need for payment innovations to provide a way for US payers and manufacturers to share financial risk and ultimately ensure that patients can…

Japan Following PharmaBoardroom’s recent interview with Ivan Cheung, chairman of Eisai’s US affiliate and president of Eisai’s global neurology business, we take the opportunity to look back on the interesting history and particularities of Japanese pharma companies’ entry and expansion into the US market.   Japan is one of the world’s…